An explosion of 503B compounding of these three substances, semaglutide, tirzepatide, and liraglutide, would dramatically increase the compounded medicine supply which is not serialized, and therefore, not traceable
It contains the nitro (-NO 2 ) group, reduction takes place in this group and it is converted into the amino (-NH 2 ) group and the remaining structure is the same
Their uptake has varied across patient populations, raising questions about evolving clinical practice
Evidence Limitations and Unanswered Questions The main evidence limitations for GHK-Cu are uneven human data, formulation differences, limited injectable safety information, small topical skin studies, indirect hair evidence, and uncertain long-term outcomes [2], [6], [7], [8]
The news dropped as the cost and demand for GLP-1s was one of the dominant topics at the 2024 AHIP conference, with industry leaders expressing concern about the high price tags for many of these drugs even as questions remain about the long-term efficacy and impacts on patients